Compare Salesforce Inc (CRM) vs Vertex Pharmaceuticals Incorporated (VRTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Salesforce Inc vs Vertex Pharmaceuticals Incorporated — how do they compare? Salesforce Inc trades at $228.83 (market cap $187.48B), while Vertex Pharmaceuticals Incorporated trades at $503.25 (market cap $127.55B). The key difference: Salesforce Inc is the larger of the two by market cap, and Salesforce Inc pays a 0.77% dividend while Vertex Pharmaceuticals Incorporated pays none. Which is the better fit depends on your goals — on Pluang, investors hold Salesforce Inc for 89 Days and Vertex Pharmaceuticals Incorporated for 120 Days on average.
| CRM | VRTX | |
|---|---|---|
Market Cap | $187.48B | $127.55B |
Volume | 6,155,822 | 1,487,944 |
Sector | Technology | Health |
52-Week High | $266.23 | $557.96 |
52-Week Low | $150.12 | $407.37 |
Typical Hold Time | 89 Days | 120 Days |
Enterprise Value | $217.82B | $121.68B |
Dividend Yield | 0.77% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Salesforce (CRM) trades at $224.56, down 0.19% on the day, amid a broader software sector sell-off driven by AI disruption concerns. The stock shows strong fundamentals with consistent earnings beats (Q2 2026 EPS of $5.90 vs. $3.27 expected), robust profitability (77.28% gross margin, 21.99% net margin), and healthy cash flow generation ($13.09B operating cash flow in 2025). Technical indicators remain bearish with current price near pivot point support at $224.
Outlook remains positive long-term given Salesforce's dominant market position, AI monetization growth (Agentforce ARR up 107% quarterly), and analyst consensus target of $271.91 (21% upside). Near-term risks include software sector volatility and competitive AI threats, but strong fundamentals support recovery potential from current discounted valuation levels.
Vertex Pharmaceuticals (VRTX) trades at $505.64, up 0.63% on the day, with a bearish technical signal despite a neutral oscillator reading. The company reported strong 2025 revenue of $12.00B and net income of $3.95B, with a net margin of 35%. Recent positive Phase 2b data for its kidney disease drug inaxaplin highlights pipeline expansion beyond cystic fibrosis dominance. Analyst consensus is strongly bullish with an 83.9% buy rating and a $573.50 price target, implying 13.4% upside.
The outlook for VRTX is positive, driven by its profitable core business and promising pipeline, but faces risks from clinical trial outcomes and competitive pressures. The stock's current valuation at a P/E of 29.45 is reasonable given its growth prospects, though investors should monitor execution on new drug approvals and market adoption.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Salesforce Inc
Salesforce Inc provides enterprise cloud computing solutions. The company offers customer relationship management technology that brings companies and customers together. Its Customer 360 platform helps the group to deliver a single source of truth, connecting customer data across systems, apps, and devices to help companies sell, service, market, and conduct commerce. It also offers Service Cloud for customer support, Marketing Cloud for digital marketing campaigns, Commerce Cloud as an e-commerce engine, the Salesforce Platform, which allows enterprises to build applications, and other solutions, such as MuleSoft for data integration.
Read more on CRM →About Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. In addition to its focus on cystic fibrosis, Vertex is diversifying its pipeline through gene-editing therapies such as CTX001 for beta-thalassemia and sickle-cell disease, small-molecule inhibitors targeting acute and chronic pain using non-opioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
Read more on VRTX →
